Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06811324 · ClinicalTrials.gov registry record · Phase 2
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
A Phase 2 study of Weight Loss and Obesity Prevention, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06811324: Recruiting Phase 2 study of Weight Loss and Obesity Prevention, sponsored by The University of Texas Health Science Center at San Antonio.
NCT06811324 is a Phase 2 study of Weight Loss and Obesity Prevention that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 20 participants, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06811324, a Phase 2 study of Weight Loss and Obesity Prevention, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide among older adults has been on the rise since FDA approval was issued, however the effects of tirzepatide use on functional outcomes in older adults with obesity are not well established. Recent studies show that weight loss caused by tirzepatide may be driven by substantial loss of lean muscle mass, which may contribute to weakness and frailty, particularly among older adults. The proposed pilot study aims to evaluate how treatment with tirzepatide for 6 months affects muscle mass and function among older adults, and if changes in muscle mass are linked to changes in functional status over the same time period.
Primary Outcome
Appendicular lean muscle mass assessed at baseline and at 6-month follow-up by dual-energy X-ray absorptiometry (DEXA)
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (1)
Texas
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-15 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
What NCT06811324 shows while recruiting
NCT06811324 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with Weight Loss appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT06811324 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06811324 about?
NCT06811324 is a clinical study titled "Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults". Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has bee...
What is the current status of trial NCT06811324?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-02-15. Estimated completion is 2027-06-01.
What conditions does trial NCT06811324 study?
This clinical trial studies the following conditions: Weight Loss, Obesity Prevention, GLP-1, Sarcopenia in Elderly, Cardiovascular Function.
What interventions are being tested in trial NCT06811324?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06811324?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06811324 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06811324's enrollment target sits among peer trials
20 110th of 116 higher than 6 of 116 other Weight Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fasted vs. Fed State Exercise
RECRUITING · Phase 2
-
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
RECRUITING · Phase 2
-
Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes
RECRUITING · Phase 2
-
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
RECRUITING · Phase 2
-
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI